Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Int J Med Microbiol
; 298(1-2): 127-34, 2008 Jan.
Article
em En
| MEDLINE
| ID: mdl-17897883
Cardiovascular diseases are the major cause of human death and have been linked to many different risk factors. Among them, coxsackievirus B3 (CVB3), as a member of the enterovirus group, is one of the most important infectious agents of virus-induced myocarditis. Despite the fact that the molecular structure of this pathogen has been characterized very precisely, there is no virus-specific preventive or therapeutic procedure against CVB3-induced heart disease in clinical use today. A promising approach to prevent CVB3-caused myocarditis represents the mutation of the viral genome in a way that coding sequences of cytokines are integrated into the viral RNA. Recombinant cytokine-expressing CVB3 variants were established to increase the local cytokine concentration and to modulate TH1-/TH2-specific immune responses. Especially protective against CVB3-induced murine myocarditis is the application of an interferon-gamma (IFN-gamma)-expressing recombinant coxsackievirus variant. The local and simultaneous expression of an immuno-relevant cytokine by the virus itself induces a strong and long-lasting immune response which protects laboratory animals against lethal infections.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Vacinas Virais
/
Enterovirus Humano B
/
Infecções por Coxsackievirus
/
Miocardite
Tipo de estudo:
Risk_factors_studies
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Int J Med Microbiol
Assunto da revista:
MICROBIOLOGIA
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Alemanha